Management of melioidosis

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 3, 2006, Pages 445-455

  Wuthiekanun, Vanaporn ^a   Peacock, Sharon J ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Burkholderia pseudomallei; Management; Melioidosis; Treatment

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBENICILLIN; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; IMIPENEM; MACROLIDE; MEROPENEM; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHOXAZOLE; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AUSTRALIA; BURKHOLDERIA PSEUDOMALLEI; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG INDICATION; DRUG MONITORING; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HEALTH CARE COST; HUMAN; MELIOIDOSIS; MORTALITY; NONHUMAN; OUTCOMES RESEARCH; PRACTICE GUIDELINE; RECURRENT INFECTION; RELAPSE; REVIEW; THAILAND; TREATMENT FAILURE; TREATMENT INDICATION;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DRUG MONITORING; DRUG RESISTANCE, BACTERIAL; HUMANS; MELIOIDOSIS; MICROBIAL SENSITIVITY TESTS;

EID: 33745187581     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.3.445     Document Type: Review

References (85)

1. White NJ. Melioidosis. Lancet 361, 1715-1722 (2003).
2. Currie BJ, Fisher DA, Howard DM et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin. Infect. Dis. 31, 981-986 (2000).
3. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18, 383-416 (2005).
4. Currie BJ, Jacups SP, Cheng AC et al. Melioidosis epidemiology and risk factors from a prospective whole-population study in northern Australia. Trop. Med. Int. Health 9, 1167-1174 (2004).
5. Puthucheary SD, Parasakthi N, Lee MK. Septicaemic melioidosis: a review of 50 cases from Malaysia. Trans. R Soc. Trop. Med. Hyg. 86, 683-685 (1992).
6. Suputtamongkol Y, Chaowagul W, Chetchotisakd P et al. Risk factors for melioidosis and bacteremic melioidosis. Clin. Infect. Dis. 29, 408-413 (1999).
7. Currie BJ, Fisher DA, Howard DM et al. The epidemiology of melioidosis in Australia and Papua New Guinea. Acta Trop. 74, 121-127 (2000).
8. Chierakul W, Winothai W, Wattanawaitunechai C et al. Melioidosis in 6 tsunami survivors in southern Thailand. Clin. Infect. Dis. 41, 982-990 (2005).
9. Mays EE, Ricketts EA. Melioidosis: recrudescence associated with bronchogenic carcinoma twenty-six years following initial geographic exposure. Chest 68, 261-263 (1975).
10. Chodimella U, Hoppes WL, Whalen S, Ognibene AJ, Rutecki GW. Septicemia and suppuration in a Vietnam veteran. Hosp. Pract. 32, 219-221 (1997).
11. Ngauy V, Lemeshev Y, Sadkowski L, Crawford G. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J. Clin. Microbiol. 43, 970-972 (2005).
12. Chadwick DR, Ang B, Sitoh YY, Lee CC. Cerebral melioidosis in Singapore: a review of five cases. Trans. R Soc. Trop. Med. Hyg. 96, 72-76 (2002).
13. Dance DA, Davis TM, Wattanagoon Y et al. Acute suppurative parotitis caused by Pseudamonas pseudomallei in children. J. Infect. Dis. 159, 654-660 (1989).
14. Tiangpitayakorn C, Songsivilai S, Piyasangthong N, Dharakul T. Speed of detection of Burkholderia pseudomallei in blood cultures and its correlation with the clinical outcome. Am. J. Trop. Med. Hyg. 57, 96-99 (1997).
15. Walsh AL, Smith MD, Wuthiekanun V et al. Prognostic significance of quantitative bacteremia in septicemic melioidosis. Clin. Infect. Dis. 21, 1498-500 (1995).
16. Limmathurotsakul D, Wuthiekanun V, Chierakul W et al. Role and significance of quantitative urine cultures in diagnosis of melioidosis. J. Clin. Microbiol. 43, 2274-2276 (2005).
17. Cheng AC, Jacups SP, Anstey NM, Currie BJ. A proposed scoring system for predicting mortality in melioidosis. Trans. R Soc. Trop. Med. Hyg. 97, 577-581 (2003).
18. Ashdown LR. Serial serum C-reactive protein levels as an aid to the management of melioidosis. Am. J. Trop. Med. Hyg. 46, 151-157 (1992).
19. Cheng AC, Obrien M, Jacups SP, Anstey NM, Currie BJ. C-reactive protein in the diagnosis of melioidosis. Am. J. Trop. Med. Hyg. 70, 580-582 (2004).
20. Reechaipichitkul W. Clinical manifestation of pulmonary melioidosis in adults. Southeast Asian J. Trop. Med. Public Health 35, 664-669 (2004).
21. Aphinives C, Pacheerat K, Chaiyakum J, Laopaiboon V, Aphinives P, Phuttharak W. Prostatic abscesses: radiographic findings and treatment. J. Med. Assoc. Thai. 87, 810-815 (2004).
22. Abbink FC, Orendi JM, de Beaufort AJ. Mother-to-child transmission of Burkbolderia pseudomallei. N. Engl. J. Med. 344, 1171-1172 (2001).
23. Ralph A, McBride J, Currie BJ. Transmission of Burkholderia pseudomallei via breast milk in northern Australia. Pediatr. Infect. Dis. J. 23, 1169-1171 (2004).
24. McCormick JB, Sexton DJ, McMurray JG, Carey E, Hayes P, Feldman RA. Human-to-human transmission of Pseudomonas pseudomallei. Ann. Intern. Med. 83, 512-513 (1975).
25. Kunakorn M, Jayanetra P, Tanphaichitra D. Man-to-man transmission of melioidosis. Lancet 337, 1290-1291 (1991).
26. Holland DJ, Wesley A, Drinkovic D, Currie BJ. Cystic fibrosis and Burkholderia pseudomallei infection: an emerging problem? Clin. Infect. Dis. 35, e138-e140 (2002).
27. Ashdown LR. Nosocomial infection due to Pseudomonas pseudomallei. two cases and an epidemiologic study. Rev. Infect. Dis. 1, 891-894 (1979).
28. Ashdown LR. In vitro activities of the newer β-lactam and quinolone antimicrobial agents against Pseudomonas pseudomallei. Antimicrob. Agents Chemother. 32, 1435-1436 (1988).
29. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J. Antimicrob. Chemother. 54, 1134-1138 (2004).
30. McEniry DW, Gillespie SH, Felmingham D. Susceptibility of Pseudomonas pseudomallei to new β-lactam and aminoglycoside antibiotics. J. Antimicrob. Chemother. 21, 171-175 (1988).
31. Smith MD, Wuthiekanun V, Walsh AL, White NJ. In-vitro activity of carbapenem antibiotics against β-lactam susceptible and resistant strains of Burkholderia pseudomallei. J. Antimicrob. Chemother. 37, 611-615 (1996).
32. Dance DA, Wuthiekanun V, Chaowagul W, White NJ. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J. Antimicrob. Chemother. 24, 295-309 (1989).
33. Winton MD, Everett ED, Dolan SA. Activities of five new fluoroquinolones against Pseudomonas pseudomallei. Antimicrob. Agents Chemother. 32, 928-929 (1988).
34. Ho PL, Cheung TK, Kinoshita R, Tse CW, Yuen KY, Chau PY. Activity of five fluoroquinolones against 71 isolates of Burkholderia pseudomallei. J. Antimicrob. Chemother. 49, 1042-1044 (2002).
35. Simpson AJ, White NJ, Wuthiekanun V. Aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob. Agents Chemother. 43, 2332 (1999).
36. Walsh AL, Smith MD, Wuthiekanun V, White NJ. Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei. evaluation of current treatment. Antimicrob. Agents Chemother. 39, 2356-2358 (1995).
37. Lumbiganon P, Tattawasatra U, Chetchotisakd P, Wongratanacheewin S, Thinkhamrop B. Comparison between the antimicrobial susceptibility of Burkholderia pseudomallei to trimethoprim-sulfamethoxazole by standard disk diffusion method and by minimal inhibitory concentration determination. J. Med. Assoc. Thai. 83, 856-860 (2000).
38. Piliouras P, Ulett GC, Ashhurst-Smith C, Hirst RG, Norton RE. A comparison of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia pseudomallei. Int. J. Antimicrob. Agents 19, 427-429 (2002).
39. Wuthiekanun V, Cheng AC, Chierakul W et al. Trimethoprim/ sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. J. Antimicrob. Chemother. 55, 1029-1031 (2005).
40. Livermore DM, Chau PY, Wong AI, Leung YK. β-lactamase of Pseudomonas pseudomallei and its contribution to antibiotic resistance. J. Antimicrob. Chemother. 20, 313-321 (1987).
41. Cheung TK, Ho PL, Woo PC, Yuen KY, Chau PY. Cloning and expression of class A β-lactamase gene blaA (BPS) in Burkholderia pseudomallei. Antimicrob. Agents Chemother. 46, 1132-1135 (2002).
42. Niumsup P, Wuthiekanun V. Cloning of the class D β-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains. J. Antimicrob. Chemother. 50, 445-455 (2002).
43. Godfrey AJ, Wong S, Dance DA, Chaowagul W, Bryan LE. Pseudomonas pseudomallei resistance to β-lactam antibiotics due to alterations in the chromosomally encoded β-lactamase. Antimicrob. Agents Chemother. 35, 1635-1640 (1991).
44. Tribuddharat C, Moore RA, Baker P, Woods DE. Burkholderia pseudomallei class A β-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. Antimicrob. Agents Chemother. 47, 2082-2087 (2003).
45. Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob. Agents Chemother. 43, 465-470 (1999).
46. Chan YY, Tan TM, Ong YM, Chua KL. BpeAB-OprB, a multidrug efflux pump in Burkholderia pseudomallei. Antimicrob. Agents Chemother. 48, 1128-1135 (2004).
47. Chan YY, Chua KL. The Burkholderia pseudomallei BpeAB-OprB efflux pump: expression and impact on quorum sensing and virulence. J. Bacteriol. 187, 4707-4719 (2005).
48. Burtnick MN, Woods DE. Isolation of polymyxin B-susceptible mutants of Burkholderia pseudomallei and molecular characterization of genetic loci involved in polymyxin B resistance. Antimicrob. Agents Chemother. 43, 2648-2656 (1999).
49. Holden MT, Titball RW, Peacock SJ et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc. Natl Acad. Sci. USA 101, 14240-14245 (2004).
50. Jenney AW, Lum G, Fisher DA, Currie BJ. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int. J. Antimicrob. Agents 17, 109-113 (2001).
51. Chen K, Sun GW, Chua KL, Gan YH. Modified virulence of antibiotic-induced Burkholderia pseudomallei filaments. Antimicrob. Agents Chemother. 49, 1002-1009 (2005).
52. Haussler S, Rohde M, Steinmetz I. Highly resistant Burkholderia pseudomallei small colony variants isolated in vitro and in experimental melioidosis. Med. Microbiol. Immunol. (Berl.) 188, 91-97 (1999).
53. Vorachit M, Lam K, Jayanetra P, Costerton JW. Resistance of Pseudomonas pseudomallei growing as a biofilm on silastic discs to ceftazidime and co-trimoxazole. Antimicrob. Agents Chemother. 37, 2000-2002 (1993).
54. Russell P, Eley SM, Ellis J et al. Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. J. Antimicrob. Chemother. 45, 813-818 (2000).
55. Ulett GC, Norton RE, Hirst RG. Combination antimicrobial therapy of acute Burkholderia pseudomallei infection in a mouse model. Pathology 31, 264-267 (1999).
56. Ulett GC, Hirst R, Bowden B, Powell K, Norton R. A comparison of antibiotic regimens in the treatment of acute melioidosis in a mouse model. J. Antimicrob. Chemother. 51, 77-81 (2003).
57. White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet 2, 697-701 (1989).
58. Sookpranee M, Boonma P, Susaengrat W, Bhuripanyo K, Punyagupta S. Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis. Antimicrob. Agents Chemother. 36, 158-162 (1992).
59. Thamprajamchit S, Chetchotisakd P, Thinkhamrop B. Cefoperazone/sulbactam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study. J. Med. Assoc. Thai. 81, 265-271 (1998).
60. Chetchotisakd P, Porramatikul S, Mootsikapun P, Anunnatsiri S, Thinkhamrop B. Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis. Clin. Infect. Dis. 33, 29-34 (2001).
61. Chierakul W, Anunnatsiri S, Short JM et al. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis. Clin. Infect. Dis. 41, 1105-1113 (2005).
62. Suputtamongkol Y, Rajchanuwong A, Chaowagul W et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin. Infect. Dis. 19, 846-853 (1994).
63. Simpson AJ, Suputtamongkol Y, Smith MD et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin. Infect. Dis. 29, 381-387 (1999).
64. Cheng AC, Fisher DA, Anstey NM, Stephens DP, Jacups SP, Currie BJ. Outcomes of patients with melioidosis treated with meropenem. Antimicrob. Agents Chemother. 48, 1763-1765 (2004).
65. Rajchanuvong A, Chaowagul W, Suputtamongkol Y, Smith MD, Dance DA, White NJ. A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis. Trans. R Soc. Trop. Med. Hyg. 89, 546-549 (1995).
66. Chaowagul W, Simpson AJ, Suputtamongkol Y, Smith MD, Angus BJ, White NJ. A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. Clin. Infect. Dis. 29, 375-380 (1999).
67. Chetchotisakd P, Chaowagul W, Mootsikapun P, Budhsarawong D, Thinkamrop B. Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline. Am. J. Trop. Med. Hyg. 64, 24-27 (2001).
68. Chaowagul W, Suputtamongkul Y, Smith MD, White NJ. Oral fluoroquinolones for maintenance treatment of melioidosis. Trans. R Soc. Trop. Med. Hyg. 91, 599-601 (1997).
69. Chaowagul W, Chierakul W, Simpson AJ et al. Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis. Antimicrob. Agents Chemother. 49, 4020-4025 (2005).
70. Angus BJ, Smith MD, Suputtamongkol Y et al. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br. J. Clin. Pharmacol. 50, 184-191 (2000).
71. Huffam S, Jacups SP, Kittler P, Currie BJ. Out of hospital treatment of patients with melioidosis using ceftazidime in 24 h elastomeric infusors, via peripherally inserted central catheters. Trop. Med. Int. Health 9, 715-717 (2004).
72. Simpson AJ, Dance DA, Wuthiekanun V, White NJ. Serum bactericidal and inhibitory titres in the management of melioidosis. J. Antimicrob. Chemother. 45, 123-127 (2000).
73. Soontornpas C, Saraya S, Chulasiri M, Chindavijak B, Mootsikapun P. Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion for treatment of septicaemic melioidosis. Int. J. Antimicrob. Agents 26, 403-407 (2005).
74. Currie BJ, Fisher DA, Anstey NM, Jacups SP. Melioidosis: acute and chronic disease, relapse and re-activation. Trans. R Soc. Trop. Med. Hyg. 94, 301-304 (2000).
75. Maharjan B, Chantratita N, Vesaratchavest M et al. Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse. J. Clin. Microbiol. 43, 6032-6034 (2005).
76. Samuel M, Ti TY. Interventions for treating melioidosis. Cochrane Database Syst. Rev. 2, CD001263 (2001).
77. Samuel M, Ti TY. Interventions for treating melioidosis. Cochrane Database Syst. Rev. 4, CD001263 (2002).
78. Currie B. Combination antimicrobial therapy for severe melioidosis. Australian Society for Antimicrobials Newsletter. 23, 16 (2005).
79. Bossi P, Tegnell A, Baka A et al. Bichat guidelines for the clinical management of glanders and melioidosis and bioterrorism-related glanders and melioidosis. Euro. Surveill. 9, E17-E18 (2004).
80. Cheng AC, Dance DA, Currie BJ. Bioterrorism, glanders and melioidosis. Euro. Surveill. 10, E1-E2 (2005).
81. Cheng AC, Stephens DP, Ansley NM, Currie BJ. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin. Infect. Dis. 38, 32-37 (2004).
82. Suputtamongkol Y, Intaranongpai S, Smith MD et al. A double-blind placebo-controlled study of an infusion of lexipafant (platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrob. Agents Chemother. 44, 693-696 (2000).
83. Rivers E, Nguyen B, Havstad S et al.; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J Med. 345, 1368-1377 (2001).
84. van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345, 1359-1367 (2001).
85. Bernard GR, Vincent JL, Laterre PF et al. Recombinant human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709 (2001).